Sulzberger Gabrielle 4

What Happened

• Gabrielle Sulzberger, a director of Eli Lilly & Co. (LLY), was granted/received 4.762 shares (transaction code A — award/acquisition) on January 20, 2026. The filing reports a per‑share value of $1,041.29, for a total grant value of approximately $4,959.
• This was an award (deferred director compensation), not an open‑market purchase or sale, and therefore is routine compensation rather than a trading signal.

Key Details

• Transaction date: 2026-01-20; reported filing date: 2026-01-21 (appears timely under Form 4 rules).
• Price used for valuation: $1,041.29 per share; total value ≈ $4,959.
• Shares acquired: 4.762. Shares owned after the transaction are not specified in the provided filing details.
• Footnote: At the reporting person’s election, the shares were deferred in lieu of cash under the Lilly Directors' Deferral Plan and will be settled in shares following the reporting person's separation from service (F1).
• Transaction code: A = Award/Acquisition.

Context

• Director awards like this are typically part of routine compensation and, when deferred, are administrative in nature; they do not necessarily reflect the director’s view on the company’s short‑term stock outlook.
• The grant amount (~$5k) is modest for director compensation and should be viewed as regular pay deferral rather than a material insider investment.